April 01, 2022 11:44 am
Participants were selected from national disease surveillance and vaccination databases if they had a PCR confirmed SARS-CoV-2 reinfection, at least 90 days after they contracted the initial infection (22,566 people in total).
January 13, 2022 7:29 pm
🔴 The vaccine, sold as Covishield in India and Vaxzevria elsewhere, also enhanced the body’s immune response to the virus’s Alpha, Beta, Delta and Gamma variants also, AstraZeneca added.
December 30, 2021 7:58 pm
The antibodies identified by the scientists target areas of the virus spike protein that remain unchanged as it mutates.
December 24, 2021 11:27 am
The AstraZeneca vaccine, being marketed under the brand names Covishield, manufactured in India, and Vaxzevria, produced in South Korea, was developed at the laboratories of the University of Oxford. The current study was conducted by a different team of researchers at the same university.
December 23, 2021 6:02 pm
🔴 Coronavirus infections have soared across much of the world as the highly infectious Omicron variant has spread, triggering new curbs in many countries.
December 18, 2021 8:49 am
About 2 per cent of the global population is considered at increased risk of an inadequate response to a Covid-19 vaccine.
December 07, 2021 9:49 am
If the AstraZeneca-Oxford vaccine is followed by a Moderna or Novavax shot, higher antibodies and T-cell responses were induced versus two doses of AstraZeneca-Oxford, according to researchers at the University of Oxford.
December 03, 2021 1:26 am
🔴 Lancet's COV-BOOST study, based on a UK trial, looked at the safety, immune response and side-effects of seven vaccines when used as a third booster jab after 10-11 weeks.
December 02, 2021 10:02 pm
The clots have been more common after a first dose than second, with 426 cases reported to the UK regulator as of Nov. 17 from more than 24 million first and second shots given.
November 23, 2021 1:43 pm
AstraZeneca, based in the UK, had licensed coronavirus-neutralising antibodies from Vanderbilt University, US, in June 2020, and had advanced a pair of these monoclonal antibodies mAbs into clinical development.